Global Phase III clinical trial of zabadinostat in combination with an immune checkpoint inhibitor for micro-satellite stable colorectal cancer
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Zabinostat (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Jan 2023 According to a Celleron Therapeutics media release, Celleron Therapeutics has merged with the Argonaut Therapeutics to form IngenOx Therapeutics (www.ingenox.com).
- 08 Jul 2022 New trial record
- 29 Jun 2022 According to a Celleron Therapeutics media release, the company expect to initiate this trial in 2022.